eli lilly clinical trials tirzepatide Breaking: New Retatrutide trial data just released. TRIUMPH-1 study results on the triple agonist. Lilly's trial on Retatrutide (triple agonist compound). 80 weeks. Phase 3 data. The results: At 12mg Mounjaro more effective than Ozempic

The DELIVER trial randomized 6,263 patients with symptomatic HF, 74% of whom had NYHA class II symptoms, either with HF with moderately reduced ejection fraction (HFmrEF

Akkermansia muciniphila ) as well as Firmicutes ( Clostridiales , Oscillospiraceae )

In 2025, Ozempic was approved by the US Food and Drug Administration (FDA) to reduce the risk of worsening kidney disease and kidney failure in people with type 2 diabetes

It's possible that these oral medications may be underdosed for some, which would lead to a monthly increase of $100 on those plans.4 Henrys pricing for its other medications is about on par with the competition